Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
D M ShinScott M Lippman

Abstract

To assess the activity and toxicity profile of combined taxol (paclitaxel), ifosfamide, and platinum (cisplatin) (TIP) in patients with recurrent or metastatic squamous cell carcinoma (SCC) of the head and neck. Recurrent or metastatic head and neck SCC patients received paclitaxel 175 mg/m2 in a 3-hour infusion on day 1; ifosfamide 1,000 mg/m2 in a 2-hour infusion on days 1 through 3; mesna 600 mg/m2 on days 1 through 3; and cisplatin 60 mg/m2 on day 1, repeated every 3 to 4 weeks. All were premedicated with dexamethasone, diphenhydramine, and cimetidine. Prophylactic hematopoietic growth factors were not permitted. Fifty-two patients were assessable for response and toxicity; 53 for survival (local-regional recurrence alone in 57% and distant metastasis with or without local-regional recurrence in 43%). Overall response rate was 58% (30 of 52) of patients; complete response rate was 17% (nine of 52) of patients, with six complete responses that continued for a median 15.7+ months. Median follow-up of all patients was 17.7 months. Median survival was 8.8 months (95% confidence interval [CI] 8.1 to 17.5 months). Toxicity was relatively well tolerated and caused no deaths. The most frequent moderate-to-severe toxicity (90% of pa...Continue Reading

Citations

Mar 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bonnie S GlissonArlene A Forastiere
Jul 25, 2014·British Journal of Cancer·P-H ChiangY-C Shen
Oct 30, 2015·Expert Opinion on Pharmacotherapy·Tobenna Nwizu, David Adelstein
Oct 8, 1999·Journal of the National Cancer Institute·J E Groopman, L M Itri
Jan 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C KosmasC Koufos
Sep 28, 2001·The Annals of Pharmacotherapy·P E Kintzel
Jul 8, 2000·The Oncologist·D Schrijvers, J B Vermorken
Feb 22, 2002·International Journal of Cancer. Journal International Du Cancer·Christos KosmasHaralambos P Kalofonos
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W F RegineM Mohiuddin
May 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ezra E W CohenEverett E Vokes
Mar 28, 2008·Expert Review of Anticancer Therapy·Pol M Specenier, Jan B Vermorken
Mar 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F Christopher HolsingerFadlo R Khuri
Jun 19, 2010·Expert Opinion on Emerging Drugs·Christopher Fung, Jennifer R Grandis
Jul 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lance C PagliaroCurtis A Pettaway
Sep 22, 2012·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Emi MikiHitoshi Okamura
Apr 1, 2010·Indian Journal of Surgical Oncology·S Marur, A A Forastiere
Feb 2, 2012·Chemotherapy Research and Practice·Diana V GolubVivek R Sharma
Jan 5, 2020·Expert Review of Anticancer Therapy·Akhil RajendraKumar Prabhash
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A S GardenL J Peters
Jun 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A Dimitrios Colevas
Apr 9, 2008·Journal of Immunotherapy·Francesco RecchiaSilvio Rea
May 4, 2011·Expert Review of Anticancer Therapy·Jean-Pascal Machiels, Sandra Schmitz
Sep 10, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Assuntina G Sacco, Ezra E Cohen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.